Contrasting Organon & Co. (NYSE:OGN) & Finch Therapeutics Group (NASDAQ:FNCH)

Finch Therapeutics Group (NASDAQ:FNCH) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Profitability

This table compares Finch Therapeutics Group and Organon & Co.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Organon & Co.	3.41%	88.97%	6.03%

Analyst Ratings

This is a breakdown of current ratings for Finch Therapeutics Group and Organon & Co., as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0	0	0	0	0.00
Organon & Co.	2	5	0	0	1.71

Organon & Co. has a consensus price target of $11.40, suggesting a potential downside of 16.15%. Given Organon & Co.’s stronger consensus rating and higher possible upside, analysts clearly believe Organon & Co. is more favorable than Finch Therapeutics Group.

Risk & Volatility

Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Valuation and Earnings

This table compares Finch Therapeutics Group and Organon & Co.”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75 million	($8.82)	-0.83
Organon & Co.	$6.22 billion	0.57	$187.00 million	$0.77	17.66

Organon & Co. has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by insiders. Comparatively, 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Organon & Co. beats Finch Therapeutics Group on 11 of the 12 factors compared between the two stocks.

About Finch Therapeutics Group

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.